Premature Ejaculation Disorder Market in US 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	152 Pages	TechNavio	November, 2023	INF18310302

Best Price Guarantee
Price	from $2,500
Length	152 Pages
Publisher	TechNavio
Published Date	November, 2023
SKU	INF18310302

Premature Ejaculation Disorder Market In US 2024-2028

The premature ejaculation disorder market in US is forecasted to grow by USD 478.41 mn during 2023-2028, accelerating at a CAGR of 10.22% during the forecast period. The report on the premature ejaculation disorder market in US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high efficacy of off-label drugs leading to high usage by people, demand for topical drug therapies to treat premature ejaculation, and growing risk factors causing premature ejaculation.

Technavio's premature ejaculation disorder market in US is segmented as below:

By Route Of Administration

Oral
Topical

By Drug Class

SSRIs
PDE5 inhibitors
Amide anesthetics
Others

By Distribution Channel

Prescription
OTC

This study identifies the use of nanotechnology in drug delivery as one of the prime reasons driving the premature ejaculation disorder market in US growth during the next few years. Also, increasing research and development activities and emergence of novel wearable products will lead to sizable demand in the market.

The report on the premature ejaculation disorder market in US covers the following areas:

Premature ejaculation disorder market in US sizing
Premature ejaculation disorder market in US forecast
Premature ejaculation disorder market in US industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading premature ejaculation disorder market in US vendors that include Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Prinston Pharmaceutical Inc., Teva Pharmaceutical Industries Ltd., Veru Inc., VIVUS LLC, Aytu BioPharma Inc., Royalty Pharma plc, and Sebela Pharmaceuticals Inc.. Also, the premature ejaculation disorder market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Country Market Characteristics; Exhibit 04: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibit 07: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 08: Parent market; Exhibit 09: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 10: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 11: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 12: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibit 13: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibit 14: Chart on US: Year-over-year growth 2023-2028 (%); Exhibit 15: Data Table on US: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Premature ejaculation disorder market in US 2018 - 2022; Exhibit 16: Historic Market Size - Data Table on premature ejaculation disorder market in US 2018 - 2022 ($ million); 4.2 Route of Administration Segment Analysis 2018 - 2022; Exhibit 17: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million); 4.3 Drug Class Segment Analysis 2018 - 2022; Exhibit 18: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); 4.4 Distribution Channel Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 20: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 26: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Route of Administration: 6.1 Market segments; Exhibit 27: Chart on Route of Administration - Market share 2023-2028 (%); Exhibit 28: Data Table on Route of Administration - Market share 2023-2028 (%); 6.2 Comparison by Route of Administration; Exhibit 29: Chart on Comparison by Route of Administration; Exhibit 30: Data Table on Comparison by Route of Administration; 6.3 Oral - Market size and forecast 2023-2028; Exhibit 31: Chart on Oral - Market size and forecast 2023-2028 ($ million); Exhibit 32: Data Table on Oral - Market size and forecast 2023-2028 ($ million); Exhibit 33: Chart on Oral - Year-over-year growth 2023-2028 (%); Exhibit 34: Data Table on Oral - Year-over-year growth 2023-2028 (%); 6.4 Topical - Market size and forecast 2023-2028; Exhibit 35: Chart on Topical - Market size and forecast 2023-2028 ($ million); Exhibit 36: Data Table on Topical - Market size and forecast 2023-2028 ($ million); Exhibit 37: Chart on Topical - Year-over-year growth 2023-2028 (%); Exhibit 38: Data Table on Topical - Year-over-year growth 2023-2028 (%); 6.5 Market opportunity by Route of Administration; Exhibit 39: Market opportunity by Route of Administration ($ million); Exhibit 40: Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Drug Class: 7.1 Market segments; Exhibit 41: Chart on Drug Class - Market share 2023-2028 (%); Exhibit 42: Data Table on Drug Class - Market share 2023-2028 (%); 7.2 Comparison by Drug Class; Exhibit 43: Chart on Comparison by Drug Class; Exhibit 44: Data Table on Comparison by Drug Class; 7.3 SSRIs - Market size and forecast 2023-2028; Exhibit 45: Chart on SSRIs - Market size and forecast 2023-2028 ($ million); Exhibit 46: Data Table on SSRIs - Market size and forecast 2023-2028 ($ million); Exhibit 47: Chart on SSRIs - Year-over-year growth 2023-2028 (%); Exhibit 48: Data Table on SSRIs - Year-over-year growth 2023-2028 (%); 7.4 PDE5 inhibitors - Market size and forecast 2023-2028; Exhibit 49: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million); Exhibit 50: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million); Exhibit 51: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%); Exhibit 52: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%); 7.5 Amide anesthetics - Market size and forecast 2023-2028; Exhibit 53: Chart on Amide anesthetics - Market size and forecast 2023-2028 ($ million); Exhibit 54: Data Table on Amide anesthetics - Market size and forecast 2023-2028 ($ million); Exhibit 55: Chart on Amide anesthetics - Year-over-year growth 2023-2028 (%); Exhibit 56: Data Table on Amide anesthetics - Year-over-year growth 2023-2028 (%); 7.6 Others - Market size and forecast 2023-2028; Exhibit 57: Chart on Others - Market size and forecast 2023-2028 ($ million); Exhibit 58: Data Table on Others - Market size and forecast 2023-2028 ($ million); Exhibit 59: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibit 60: Data Table on Others - Year-over-year growth 2023-2028 (%); 7.7 Market opportunity by Drug Class; Exhibit 61: Market opportunity by Drug Class ($ million); Exhibit 62: Data Table on Market opportunity by Drug Class ($ million)
8 Market Segmentation by Distribution Channel: 8.1 Market segments; Exhibit 63: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibit 64: Data Table on Distribution Channel - Market share 2023-2028 (%); 8.2 Comparison by Distribution Channel; Exhibit 65: Chart on Comparison by Distribution Channel; Exhibit 66: Data Table on Comparison by Distribution Channel; 8.3 Prescription - Market size and forecast 2023-2028; Exhibit 67: Chart on Prescription - Market size and forecast 2023-2028 ($ million); Exhibit 68: Data Table on Prescription - Market size and forecast 2023-2028 ($ million); Exhibit 69: Chart on Prescription - Year-over-year growth 2023-2028 (%); Exhibit 70: Data Table on Prescription - Year-over-year growth 2023-2028 (%); 8.4 OTC - Market size and forecast 2023-2028; Exhibit 71: Chart on OTC - Market size and forecast 2023-2028 ($ million); Exhibit 72: Data Table on OTC - Market size and forecast 2023-2028 ($ million); Exhibit 73: Chart on OTC - Year-over-year growth 2023-2028 (%); Exhibit 74: Data Table on OTC - Year-over-year growth 2023-2028 (%); 8.5 Market opportunity by Distribution Channel; Exhibit 75: Market opportunity by Distribution Channel ($ million); Exhibit 76: Data Table on Market opportunity by Distribution Channel ($ million)
9 Customer Landscape: 9.1 Customer landscape overview; Exhibit 77: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 78: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 79: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 80: Overview on factors of disruption; 11.4 Industry risks; Exhibit 81: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 82: Vendors covered; 12.2 Market positioning of vendors; Exhibit 83: Matrix on vendor position and classification; 12.3 Absorption Pharmaceuticals LLC; Exhibit 84: Absorption Pharmaceuticals LLC - Overview; Exhibit 85: Absorption Pharmaceuticals LLC - Product / Service; Exhibit 86: Absorption Pharmaceuticals LLC - Key offerings; 12.4 Alembic Pharmaceuticals Ltd.; Exhibit 87: Alembic Pharmaceuticals Ltd. - Overview; Exhibit 88: Alembic Pharmaceuticals Ltd. - Product / Service; Exhibit 89: Alembic Pharmaceuticals Ltd. - Key offerings; 12.5 Amneal Pharmaceuticals Inc.; Exhibit 90: Amneal Pharmaceuticals Inc. - Overview; Exhibit 91: Amneal Pharmaceuticals Inc. - Business segments; Exhibit 92: Amneal Pharmaceuticals Inc. - Key news; Exhibit 93: Amneal Pharmaceuticals Inc. - Key offerings; Exhibit 94: Amneal Pharmaceuticals Inc. - Segment focus; 12.6 Aytu BioPharma Inc.; Exhibit 95: Aytu BioPharma Inc. - Overview; Exhibit 96: Aytu BioPharma Inc. - Product / Service; Exhibit 97: Aytu BioPharma Inc. - Key offerings; 12.7 Bayer AG; Exhibit 98: Bayer AG - Overview; Exhibit 99: Bayer AG - Business segments; Exhibit 100: Bayer AG - Key news; Exhibit 101: Bayer AG - Key offerings; Exhibit 102: Bayer AG - Segment focus; 12.8 Cipla Ltd.; Exhibit 103: Cipla Ltd. - Overview; Exhibit 104: Cipla Ltd. - Business segments; Exhibit 105: Cipla Ltd. - Key news; Exhibit 106: Cipla Ltd. - Key offerings; Exhibit 107: Cipla Ltd. - Segment focus; 12.9 Eli Lilly and Co.; Exhibit 108: Eli Lilly and Co. - Overview; Exhibit 109: Eli Lilly and Co. - Product / Service; Exhibit 110: Eli Lilly and Co. - Key news; Exhibit 111: Eli Lilly and Co. - Key offerings; 12.10 Johnson and Johnson; Exhibit 112: Johnson and Johnson - Overview; Exhibit 113: Johnson and Johnson - Business segments; Exhibit 114: Johnson and Johnson - Key news; Exhibit 115: Johnson and Johnson - Key offerings; Exhibit 116: Johnson and Johnson - Segment focus; 12.11 NeuroHealing Pharmaceuticals Inc.; Exhibit 117: NeuroHealing Pharmaceuticals Inc. - Overview; Exhibit 118: NeuroHealing Pharmaceuticals Inc. - Product / Service; Exhibit 119: NeuroHealing Pharmaceuticals Inc. - Key offerings; 12.12 Novartis AG; Exhibit 120: Novartis AG - Overview; Exhibit 121: Novartis AG - Business segments; Exhibit 122: Novartis AG - Key offerings; Exhibit 123: Novartis AG - Segment focus; 12.13 Pfizer Inc.; Exhibit 124: Pfizer Inc. - Overview; Exhibit 125: Pfizer Inc. - Product / Service; Exhibit 126: Pfizer Inc. - Key news; Exhibit 127: Pfizer Inc. - Key offerings; 12.14 Sebela Pharmaceuticals Inc.; Exhibit 128: Sebela Pharmaceuticals Inc. - Overview; Exhibit 129: Sebela Pharmaceuticals Inc. - Product / Service; Exhibit 130: Sebela Pharmaceuticals Inc. - Key offerings; 12.15 Teva Pharmaceutical Industries Ltd.; Exhibit 131: Teva Pharmaceutical Industries Ltd. - Overview; Exhibit 132: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibit 133: Teva Pharmaceutical Industries Ltd. - Key news; Exhibit 134: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibit 135: Teva Pharmaceutical Industries Ltd. - Segment focus; 12.16 Veru Inc.; Exhibit 136: Veru Inc. - Overview; Exhibit 137: Veru Inc. - Business segments; Exhibit 138: Veru Inc. - Key offerings; Exhibit 139: Veru Inc. - Segment focus; 12.17 VIVUS LLC; Exhibit 140: VIVUS LLC - Overview; Exhibit 141: VIVUS LLC - Product / Service; Exhibit 142: VIVUS LLC - Key offerings
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 143: Inclusions checklist; Exhibit 144: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 145: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 146: Research methodology; Exhibit 147: Validation techniques employed for market sizing; Exhibit 148: Information sources; 13.5 List of abbreviations; Exhibit 149: List of abbreviations; Exhibits:; Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibits7: Executive Summary - Chart on Vendor Market Positioning; Exhibits8: Parent market; Exhibits9: Market Characteristics; Exhibits10: Offerings of vendors included in the market definition; Exhibits11: Market segments; Exhibits12: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibits13: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibits14: Chart on US: Year-over-year growth 2023-2028 (%); Exhibits15: Data Table on US: Year-over-year growth 2023-2028 (%); Exhibits16: Historic Market Size - Data Table on premature ejaculation disorder market in US 2018 - 2022 ($ million); Exhibits17: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million); Exhibits18: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); Exhibits19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million); Exhibits20: Five forces analysis - Comparison between 2023 and 2028; Exhibits21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits23: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits24: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits25: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits26: Chart on Market condition - Five forces 2023 and 2028; Exhibits27: Chart on Route of Administration - Market share 2023-2028 (%); Exhibits28: Data Table on Route of Administration - Market share 2023-2028 (%); Exhibits29: Chart on Comparison by Route of Administration; Exhibits30: Data Table on Comparison by Route of Administration; Exhibits31: Chart on Oral - Market size and forecast 2023-2028 ($ million); Exhibits32: Data Table on Oral - Market size and forecast 2023-2028 ($ million); Exhibits33: Chart on Oral - Year-over-year growth 2023-2028 (%); Exhibits34: Data Table on Oral - Year-over-year growth 2023-2028 (%); Exhibits35: Chart on Topical - Market size and forecast 2023-2028 ($ million); Exhibits36: Data Table on Topical - Market size and forecast 2023-2028 ($ million); Exhibits37: Chart on Topical - Year-over-year growth 2023-2028 (%); Exhibits38: Data Table on Topical - Year-over-year growth 2023-2028 (%); Exhibits39: Market opportunity by Route of Administration ($ million); Exhibits40: Data Table on Market opportunity by Route of Administration ($ million); Exhibits41: Chart on Drug Class - Market share 2023-2028 (%); Exhibits42: Data Table on Drug Class - Market share 2023-2028 (%); Exhibits43: Chart on Comparison by Drug Class; Exhibits44: Data Table on Comparison by Drug Class; Exhibits45: Chart on SSRIs - Market size and forecast 2023-2028 ($ million); Exhibits46: Data Table on SSRIs - Market size and forecast 2023-2028 ($ million); Exhibits47: Chart on SSRIs - Year-over-year growth 2023-2028 (%); Exhibits48: Data Table on SSRIs - Year-over-year growth 2023-2028 (%); Exhibits49: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits50: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits51: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%); Exhibits52: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%); Exhibits53: Chart on Amide anesthetics - Market size and forecast 2023-2028 ($ million); Exhibits54: Data Table on Amide anesthetics - Market size and forecast 2023-2028 ($ million); Exhibits55: Chart on Amide anesthetics - Year-over-year growth 2023-2028 (%); Exhibits56: Data Table on Amide anesthetics - Year-over-year growth 2023-2028 (%); Exhibits57: Chart on Others - Market size and forecast 2023-2028 ($ million); Exhibits58: Data Table on Others - Market size and forecast 2023-2028 ($ million); Exhibits59: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibits60: Data Table on Others - Year-over-year growth 2023-2028 (%); Exhibits61: Market opportunity by Drug Class ($ million); Exhibits62: Data Table on Market opportunity by Drug Class ($ million); Exhibits63: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibits64: Data Table on Distribution Channel - Market share 2023-2028 (%); Exhibits65: Chart on Comparison by Distribution Channel; Exhibits66: Data Table on Comparison by Distribution Channel; Exhibits67: Chart on Prescription - Market size and forecast 2023-2028 ($ million); Exhibits68: Data Table on Prescription - Market size and forecast 2023-2028 ($ million); Exhibits69: Chart on Prescription - Year-over-year growth 2023-2028 (%); Exhibits70: Data Table on Prescription - Year-over-year growth 2023-2028 (%); Exhibits71: Chart on OTC - Market size and forecast 2023-2028 ($ million); Exhibits72: Data Table on OTC - Market size and forecast 2023-2028 ($ million); Exhibits73: Chart on OTC - Year-over-year growth 2023-2028 (%); Exhibits74: Data Table on OTC - Year-over-year growth 2023-2028 (%); Exhibits75: Market opportunity by Distribution Channel ($ million); Exhibits76: Data Table on Market opportunity by Distribution Channel ($ million); Exhibits77: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits78: Impact of drivers and challenges in 2023 and 2028; Exhibits79: Overview on Criticality of inputs and Factors of differentiation; Exhibits80: Overview on factors of disruption; Exhibits81: Impact of key risks on business; Exhibits82: Vendors covered; Exhibits83: Matrix on vendor position and classification; Exhibits84: Absorption Pharmaceuticals LLC - Overview; Exhibits85: Absorption Pharmaceuticals LLC - Product / Service; Exhibits86: Absorption Pharmaceuticals LLC - Key offerings; Exhibits87: Alembic Pharmaceuticals Ltd. - Overview; Exhibits88: Alembic Pharmaceuticals Ltd. - Product / Service; Exhibits89: Alembic Pharmaceuticals Ltd. - Key offerings; Exhibits90: Amneal Pharmaceuticals Inc. - Overview; Exhibits91: Amneal Pharmaceuticals Inc. - Business segments; Exhibits92: Amneal Pharmaceuticals Inc. - Key news; Exhibits93: Amneal Pharmaceuticals Inc. - Key offerings; Exhibits94: Amneal Pharmaceuticals Inc. - Segment focus; Exhibits95: Aytu BioPharma Inc. - Overview; Exhibits96: Aytu BioPharma Inc. - Product / Service; Exhibits97: Aytu BioPharma Inc. - Key offerings; Exhibits98: Bayer AG - Overview; Exhibits99: Bayer AG - Business segments; Exhibits100: Bayer AG - Key news; Exhibits101: Bayer AG - Key offerings; Exhibits102: Bayer AG - Segment focus; Exhibits103: Cipla Ltd. - Overview; Exhibits104: Cipla Ltd. - Business segments; Exhibits105: Cipla Ltd. - Key news; Exhibits106: Cipla Ltd. - Key offerings; Exhibits107: Cipla Ltd. - Segment focus; Exhibits108: Eli Lilly and Co. - Overview; Exhibits109: Eli Lilly and Co. - Product / Service; Exhibits110: Eli Lilly and Co. - Key news; Exhibits111: Eli Lilly and Co. - Key offerings; Exhibits112: Johnson and Johnson - Overview; Exhibits113: Johnson and Johnson - Business segments; Exhibits114: Johnson and Johnson - Key news; Exhibits115: Johnson and Johnson - Key offerings; Exhibits116: Johnson and Johnson - Segment focus; Exhibits117: NeuroHealing Pharmaceuticals Inc. - Overview; Exhibits118: NeuroHealing Pharmaceuticals Inc. - Product / Service; Exhibits119: NeuroHealing Pharmaceuticals Inc. - Key offerings; Exhibits120: Novartis AG - Overview; Exhibits121: Novartis AG - Business segments; Exhibits122: Novartis AG - Key offerings; Exhibits123: Novartis AG - Segment focus; Exhibits124: Pfizer Inc. - Overview; Exhibits125: Pfizer Inc. - Product / Service; Exhibits126: Pfizer Inc. - Key news; Exhibits127: Pfizer Inc. - Key offerings; Exhibits128: Sebela Pharmaceuticals Inc. - Overview; Exhibits129: Sebela Pharmaceuticals Inc. - Product / Service; Exhibits130: Sebela Pharmaceuticals Inc. - Key offerings; Exhibits131: Teva Pharmaceutical Industries Ltd. - Overview; Exhibits132: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibits133: Teva Pharmaceutical Industries Ltd. - Key news; Exhibits134: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibits135: Teva Pharmaceutical Industries Ltd. - Segment focus; Exhibits136: Veru Inc. - Overview; Exhibits137: Veru Inc. - Business segments; Exhibits138: Veru Inc. - Key offerings; Exhibits139: Veru Inc. - Segment focus; Exhibits140: VIVUS LLC - Overview; Exhibits141: VIVUS LLC - Product / Service; Exhibits142: VIVUS LLC - Key offerings; Exhibits143: Inclusions checklist; Exhibits144: Exclusions checklist; Exhibits145: Currency conversion rates for US$; Exhibits146: Research methodology; Exhibits147: Validation techniques employed for market sizing; Exhibits148: Information sources; Exhibits149: List of abbreviations